Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome
Joint Authors
Vargas-Camaño, María Eugenia
Alonso-Bello, Cesar Daniel
Lozano-Patiño, Fernando
Castrejón-Vázquez, María Isabel
Ynga-Durand, Mario A.
Hierro-Orozco, Sagrario
Berrón-Ruiz, Laura
Alcántara-Montiel, Julio César
Santos-Argumedo, Leopoldo
Herrera-Sánchez, Diana Andrea
Jiménez-Martínez, María C.
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-07-04
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus.
The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema.
Omalizumab is a humanized recombinant monoclonal antibody against IgE.
Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level.
We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab.
After therapy for 4 years, we observed diminished eczema and serum IgE levels.
American Psychological Association (APA)
Alonso-Bello, Cesar Daniel& Jiménez-Martínez, María C.& Vargas-Camaño, María Eugenia& Hierro-Orozco, Sagrario& Ynga-Durand, Mario A.& Berrón-Ruiz, Laura…[et al.]. 2019. Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome. Case Reports in Immunology،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1136883
Modern Language Association (MLA)
Alonso-Bello, Cesar Daniel…[et al.]. Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome. Case Reports in Immunology No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1136883
American Medical Association (AMA)
Alonso-Bello, Cesar Daniel& Jiménez-Martínez, María C.& Vargas-Camaño, María Eugenia& Hierro-Orozco, Sagrario& Ynga-Durand, Mario A.& Berrón-Ruiz, Laura…[et al.]. Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome. Case Reports in Immunology. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1136883
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1136883